Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update
Pelthos Therapeutics (NYSE American: PTHS) reported Q2 2025 financial results and significant business developments. The company completed a merger with Channel Therapeutics and secured a $50.1 million private placement financing led by Murchinson Ltd. on July 1, 2025.
Key highlights include the successful launch of ZELSUVMI™, the first FDA-approved at-home treatment for molluscum contagiosum, targeting a market of 16.7 million affected people with up to 6 million new cases annually in the US. The company has expanded its infrastructure, hiring 50 territory sales managers and growing to over 90 employees. The company's current market cap is approximately $55 million, with an implied value of $165 million post-conversion of Series A Preferred Stock.
Pelthos Therapeutics (NYSE American: PTHS) ha comunicato i risultati finanziari del secondo trimestre 2025 e importanti sviluppi aziendali. La società ha completato la fusione con Channel Therapeutics e, il 1° luglio 2025, ha ottenuto un finanziamento in private placement da 50,1 milioni di dollari guidato da Murchinson Ltd.
Tra i punti salienti c'è il lancio riuscito di ZELSUVMI™, il primo trattamento domiciliare approvato dalla FDA per la molluscum contagiosum, rivolto a un mercato di circa 16,7 milioni di persone affette e fino a 6 milioni di nuovi casi annui negli Stati Uniti. L'azienda ha ampliato la propria struttura, assumendo 50 territory sales manager e arrivando a oltre 90 dipendenti. La capitalizzazione di mercato attuale è di circa 55 milioni di dollari, con un valore implicito di 165 milioni di dollari dopo la conversione delle azioni privilegiate di Serie A.
Pelthos Therapeutics (NYSE American: PTHS) informó los resultados financieros del segundo trimestre de 2025 y avances empresariales relevantes. La compañía completó la fusión con Channel Therapeutics y, el 1 de julio de 2025, aseguró un financiamiento en colocación privada de 50,1 millones de dólares liderado por Murchinson Ltd.
Entre los hitos destaca el exitoso lanzamiento de ZELSUVMI™, el primer tratamiento domiciliario aprobado por la FDA para la molluscum contagiosum, dirigido a un mercado de 16,7 millones de personas afectadas y hasta 6 millones de casos nuevos anuales en EE. UU. La compañía ha ampliado su infraestructura, contratando a 50 territory sales managers y creciendo a más de 90 empleados. La capitalización bursátil actual es de aproximadamente 55 millones de dólares, con un valor implícito de 165 millones de dólares tras la conversión de las acciones preferentes Serie A.
Pelthos Therapeutics (NYSE American: PTHS)는 2025년 2분기 실적 및 주요 사업 진행 상황을 발표했습니다. 회사는 Channel Therapeutics와의 합병을 완료했으며, 2025년 7월 1일 Murchinson Ltd.가 주도한 5010만 달러 규모의 사모 자금 조달을 확보했습니다.
주요 내용으로는 FDA 승인된 가정용 최초의 molluscum contagiosum 치료제인 ZELSUVMI™의 성공적인 출시가 있으며, 이는 1670만 명 가량의 환자와 미국 내 연간 최대 600만 건의 신규 발생을 대상으로 합니다. 회사는 조직을 확장하여 영업 담당 매니저 50명을 채용하고 직원 수가 90명을 넘어섰습니다. 현재 시가총액은 약 5500만 달러이며, 시리즈 A 우선주 전환 시 암묵적 가치는 1억6500만 달러입니다.
Pelthos Therapeutics (NYSE American: PTHS) a annoncé ses résultats financiers du deuxième trimestre 2025 et des développements commerciaux significatifs. La société a finalisé sa fusion avec Channel Therapeutics et a obtenu, le 1er juillet 2025, un financement en placement privé de 50,1 millions de dollars mené par Murchinson Ltd.
Parmi les points clés figure le lancement réussi de ZELSUVMI™, le premier traitement à domicile approuvé par la FDA pour la molluscum contagiosum, visant un marché de 16,7 millions de personnes concernées et jusqu'à 6 millions de nouveaux cas par an aux États-Unis. L'entreprise a renforcé ses infrastructures en recrutant 50 territory sales managers et en dépassant les 90 employés. La capitalisation boursière actuelle est d'environ 55 millions de dollars, avec une valeur implicite de 165 millions de dollars après conversion des actions privilégiées de série A.
Pelthos Therapeutics (NYSE American: PTHS) meldete die Finanzergebnisse für das zweite Quartal 2025 sowie bedeutende Geschäftsentwicklungen. Das Unternehmen schloss die Fusion mit Channel Therapeutics ab und sicherte sich am 1. Juli 2025 eine Privatplatzierungsfinanzierung in Höhe von 50,1 Millionen US-Dollar unter Führung von Murchinson Ltd.
Zu den wichtigsten Punkten gehört der erfolgreiche Start von ZELSUVMI™, der ersten von der FDA zugelassenen Behandlung für Molluscum contagiosum zur Anwendung zu Hause, die einen Markt von rund 16,7 Millionen Betroffenen adressiert und in den USA bis zu 6 Millionen Neuerkrankungen pro Jahr umfasst. Das Unternehmen hat seine Infrastruktur ausgebaut, 50 Territory Sales Manager eingestellt und ist auf über 90 Mitarbeiter angewachsen. Die aktuelle Marktkapitalisierung beträgt etwa 55 Millionen US-Dollar, mit einem impliziten Wert von 165 Millionen US-Dollar nach Umwandlung der Series-A-Vorzugsaktien.
- Secured $50.1 million private placement financing to support ZELSUVMI launch
- Successfully launched ZELSUVMI, the first FDA-approved at-home treatment for molluscum contagiosum
- Expanded team to 90+ employees including 50 territory sales managers
- Early sales and prescriptions meeting or exceeding expectations
- Advanced discussions to acquire second FDA-approved pediatric infectious disease product
- Limited public float of only 600,000 shares of Common Stock
- Share lock-up period extends through December 31, 2025
Insights
Pelthos' successful ZELSUVMI launch and $50.1M financing bolster its new direction following merger completion, with early sales promising.
Pelthos Therapeutics has undergone a significant transformation through its completed merger with Channel Therapeutics and concurrent $50.1 million private placement financing that closed on July 1, 2025. This strategic move has positioned the company with substantially improved financial resources to support the commercial launch of ZELSUVMI, their newly FDA-approved treatment for molluscum contagiosum.
The recent launch of ZELSUVMI (berdazimer topical gel 10.3%) represents a notable advancement in treating molluscum contagiosum, a highly contagious viral skin condition affecting up to 16.7 million people in the US. As the first and only FDA-approved at-home treatment for this condition, ZELSUVMI addresses a significant unmet medical need in the pediatric dermatology market. The therapy's convenient at-home application provides a meaningful advantage over existing in-office procedures that can be painful and traumatic for children.
Pelthos has quickly scaled its commercial infrastructure, hiring 50 territory sales managers and building out its management team with key appointments. This rapid organizational expansion demonstrates the company's commitment to ensuring successful market penetration for ZELSUVMI. The early commercial traction noted by management, with orders and prescriptions reportedly meeting or exceeding sales expectations, provides initial validation of market demand.
The company's implied market capitalization of approximately $165 million (considering conversion of preferred shares) versus its current public market cap of about $55 million highlights a significant potential valuation gap. With discussions underway to acquire a second FDA-approved pediatric infectious disease product that would complement ZELSUVMI, Pelthos appears to be executing a focused strategy to build a specialized pharmaceutical company addressing underserved pediatric conditions.
- Files Quarterly Report on Form 10-Q detailing financial results for legacy operations for the three and six months ended June 30, 2025
- Strong physician response following successful launch of ZELSUVMI™ (berdazimer) topical gel
10.3% , the first and only FDA-approved at-home treatment for molluscum contagiosum for patients one year of age and older - Completes build-out of essential management operational infrastructure and hires 50 territory sales managers
DURHAM, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the “Company”) committed to commercializing innovative therapeutic products for high unmet patient needs, today reported financial results for legacy operations for the three and six months ended June 30, 2025. This will be the last set of financial results that the Company will issue solely related to the business operations of Channel Therapeutics Corporation prior to the consummation of the merger (the “Merger”) and the concurrent private placement financing that closed on July 1, 2025.
Recent Company Highlights
Completed the Merger with Channel Therapeutics and closed the
As previously announced, on July 1, 2025, Pelthos completed its Merger with and into a wholly owned subsidiary of Channel Therapeutics Corporation and closed a
The private placement was led by a group of strategic investors including Murchinson Ltd. Subject to certain exceptions, the shares of the Company’s common stock, par value
Launched ZELSUVMI (berdazimer) topical gel
On July 10, 2025, Pelthos launched ZELSUVMI, the first and only prescription therapy approved by the U.S. Food and Drug Administration (“FDA”) for use at home by patients, parents, and caregivers to treat molluscum infections, a highly contagious viral skin condition. ZELSUVMI is a novel, topical nitric oxide-releasing gel for the treatment of molluscum at the time of diagnosis. The once-daily prescription medication is effective, well tolerated, and convenient for at-home or on-the-go application and can be used to treat infections on the body, including sensitive areas such as the face, groin, or underarms. This highly contagious viral skin condition afflicts an estimated 16.7 million people, with up to 6 million new incidents every year in the United States, most of them children.i,ii
Completed build-out of management and operational infrastructure and hired 50 territory sales managers
Pelthos completed the buildout of its management, operational and sales teams in July. This follows the promotion of Sai Rangarao to Chief Commercial Officer and the appointment of Matt Rysavy to Vice President of Market Access. The Pelthos team now consists of more than 90 employees, including 50 territory sales managers focused on the commercial launch of ZELSUVMI.
Management Commentary
Scott Plesha, CEO of Pelthos, stated, “The past month has been defined by focus and execution. Since completing the Merger and closing our private placement financing in early July, we have successfully built out our commercial organization and launched our novel treatment for molluscum into the market. These early achievements position us for an exciting next chapter of growth and innovation.”
Mr. Plesha continued, “We will continue to invest in ZELSUVMI awareness programs to drive sales growth while also focusing on expanding our pipeline and monetizing our legacy pain programs, which are key components of our long-term growth strategy. Our team is currently in advanced discussions to acquire a second FDA-approved pediatric infectious disease product that would complement ZELSUVMI. We look forward to providing further updates over the coming months as we aim to create long-term value for our stockholders.”
Sai Rangarao, Pelthos Chief Commercial Officer, added, “The commercial launch of ZELSUVMI, has been positively received by healthcare practitioners, with orders and prescriptions meeting or exceeding our sales expectations. We believe ZELSUVMI addresses a significant need for HCPs, caregivers, and patients seeking an effective at-home solution to treat molluscum and to reduce or minimize the visible and psychological effects of scarring associated with this highly contagious skin condition.”
About Molluscum Contagiosum
Molluscum is a poxvirus and one of the most common skin infections seen by dermatologists, pediatric dermatologists, and pediatricians. This highly contagious viral skin condition afflicts an estimated 16.7 million people, with up to 6 million new incidents every year in the United States, most of them children.i,ii, Individuals with compromised immune systems are at an elevated risk of contracting molluscum, with the condition impacting approximately
About ZELSUVMI™ (berdazimer) topical gel,
ZELSUVMI (berdazimer) topical gel,
About Pelthos Therapeutics
Pelthos Therapeutics (NYSE American: PTHS) is a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The Company’s lead product ZELSUVMI™ (berdazimer) topical gel,
Forward-Looking Statements
This press release contains forward-looking statements, as defined in Section 21E of the Securities Exchange Act of 1934, regarding Pelthos’ current expectations. All statements, other than statements of historical fact, could be deemed to be forward-looking statements. In some instances, words such as “plans,” “believes,” “expects,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect our good faith beliefs (or those of the indicated third parties) and speak only as of the date hereof. These forward-looking statements include, without limitation, references to our expectations regarding (i) our belief that our completion of the Merger, the closing of the private placement financing, the buildout of our commercial organization and the launch of ZELSUVMI will position us for future growth and innovation, (ii) the anticipated timing of an FDA- approved pediatric infectious disease product, (iii) the belief that ZELSUVMI addresses a significant need for physicians and caregivers seeking an effective at-home solution to treat molluscum and to reduce or minimize the visible and psychological effects of scarring associated with the condition, and (vii) the Company’s future opportunities, strategy and plans in the market. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to there being no guarantee that the trading price of the combined company’s Common Stock will be indicative of the combined company’s value or that the combined company’s Common Stock will become an attractive investment in the future; we may rely on collaborative partners for milestone payments, royalties, materials revenue, contract payments and other revenue projections and may not receive expected revenue; we and our partners may not be able to timely or successfully advance any product(s) in our internal or partnered pipeline or receive regulatory approval and there may not be a market for the product(s) even if successfully developed and approved; and changes in general economic conditions, including as a result of war, conflict, epidemic diseases, the implementation of tariffs, and ongoing or future litigation could expose us to significant liabilities and have a material adverse effect on us. These and other risks and uncertainties are described more fully in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law.
Contacts
Investor Inquiries:
Mike Moyer
LifeSci Advisors, LLC
Managing Director
mmoyer@lifesciadvisors.com
Media:
KWM Communications
Kellie Walsh / Rachel Kessler
pelthos@kwmcommunications.com
(914) 315-6072
i Neal Bhatia, Adelaide A Hebert, James Q Del Rosso. Comprehensive Management of Molluscum Contagiosum: Assessment of Clinical Associations, Comorbidities, and Management Principles. Journal of Clinical and Aesthetic Dermatology. 2023 Aug;16(8 Suppl 1):S12–S17.
ii Olsen JR, Gallacher J, Finlay A, Piguet V, Francis NA. Time to resolution and effect on quality of life of molluscum contagiosum in children in the UK: a prospective community cohort study. Lancet Infect Dis. 2015;15:190-195
iii Molluscum contagiosum: overview. American Academy of Dermatology. Accessed December 9, 2024. https://www.aad.org/public/diseases/a-z/molluscum-contagiosum-overview
FAQ
What is the market size for Pelthos Therapeutics' ZELSUVMI treatment?
How much funding did Pelthos Therapeutics (PTHS) raise in their recent private placement?
What is PTHS's current market capitalization?
How many sales representatives does Pelthos Therapeutics have for ZELSUVMI?
When will Pelthos Therapeutics' share lock-up period end?
